These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 23620257)

  • 21. The Bmi-1 polycomb protein antagonizes the (-)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival.
    Balasubramanian S; Adhikary G; Eckert RL
    Carcinogenesis; 2010 Mar; 31(3):496-503. PubMed ID: 20015867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overexpression of Enhancer of zeste homolog 2 with trimethylation of lysine 27 on histone H3 in adult T-cell leukemia/lymphoma as a target for epigenetic therapy.
    Sasaki D; Imaizumi Y; Hasegawa H; Osaka A; Tsukasaki K; Choi YL; Mano H; Marquez VE; Hayashi T; Yanagihara K; Moriwaki Y; Miyazaki Y; Kamihira S; Yamada Y
    Haematologica; 2011 May; 96(5):712-9. PubMed ID: 21228036
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
    Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
    EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Polycomb-group proteins in the initiation and progression of cancer.
    Zhao X; Wu X
    J Genet Genomics; 2021 Jun; 48(6):433-443. PubMed ID: 34266781
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Global changes of H3K27me3 domains and Polycomb group protein distribution in the absence of recruiters Spps or Pho.
    Brown JL; Sun MA; Kassis JA
    Proc Natl Acad Sci U S A; 2018 Feb; 115(8):E1839-E1848. PubMed ID: 29432187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target.
    Agarwal P; Alzrigat M; Párraga AA; Enroth S; Singh U; Ungerstedt J; Österborg A; Brown PJ; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
    Oncotarget; 2016 Feb; 7(6):6809-23. PubMed ID: 26755663
    [TBL] [Abstract][Full Text] [Related]  

  • 27. No Easy Way Out for EZH2: Its Pleiotropic, Noncanonical Effects on Gene Regulation and Cellular Function.
    Wang J; Wang GG
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33327550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Polycomb group protein-mediated histone modifications during cell differentiation.
    Khan AA; Lee AJ; Roh TY
    Epigenomics; 2015; 7(1):75-84. PubMed ID: 25687468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of BMI1 with polycomb bodies is dynamic and requires PRC2/EZH2 and the maintenance DNA methyltransferase DNMT1.
    Hernández-Muñoz I; Taghavi P; Kuijl C; Neefjes J; van Lohuizen M
    Mol Cell Biol; 2005 Dec; 25(24):11047-58. PubMed ID: 16314526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oncogenic roles of enhancer of zeste homolog 1/2 in hematological malignancies.
    Nakagawa M; Kitabayashi I
    Cancer Sci; 2018 Aug; 109(8):2342-2348. PubMed ID: 29845708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Role of Polycomb Group Protein BMI1 in DNA Repair and Genomic Stability.
    Fitieh A; Locke AJ; Motamedi M; Ismail IH
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33804165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The polycomb repressive complex 2 is a potential target of SUMO modifications.
    Riising EM; Boggio R; Chiocca S; Helin K; Pasini D
    PLoS One; 2008 Jul; 3(7):e2704. PubMed ID: 18628979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Critical Roles of Polycomb Repressive Complexes in Transcription and Cancer.
    Dong GJ; Xu JL; Qi YR; Yuan ZQ; Zhao W
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076977
    [TBL] [Abstract][Full Text] [Related]  

  • 34. c-Myc-mediated epigenetic silencing of MicroRNA-101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma.
    Wang L; Zhang X; Jia LT; Hu SJ; Zhao J; Yang JD; Wen WH; Wang Z; Wang T; Zhao J; Wang RA; Meng YL; Nie YZ; Dou KF; Chen SY; Yao LB; Fan DM; Zhang R; Yang AG
    Hepatology; 2014 May; 59(5):1850-63. PubMed ID: 24002871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetic regulation of T cells by Polycomb group proteins.
    Melo GA; Calôba C; Brum G; Passos TO; Martinez GJ; Pereira RM
    J Leukoc Biol; 2022 Jun; 111(6):1253-1267. PubMed ID: 35466423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of enhancer of zeste homolog 2: From viral epigenetics to the carcinogenesis of hepatocellular carcinoma.
    Sanna L; Marchesi I; Melone MAB; Bagella L
    J Cell Physiol; 2018 Sep; 233(9):6508-6517. PubMed ID: 29574790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ezh2 requires PHF1 to efficiently catalyze H3 lysine 27 trimethylation in vivo.
    Sarma K; Margueron R; Ivanov A; Pirrotta V; Reinberg D
    Mol Cell Biol; 2008 Apr; 28(8):2718-31. PubMed ID: 18285464
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Alhaj Abed J; Ghotbi E; Ye P; Frolov A; Benes J; Jones RS
    Development; 2018 Nov; 145(23):. PubMed ID: 30389849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.
    Xiao G; Jin LL; Liu CQ; Wang YC; Meng YM; Zhou ZG; Chen J; Yu XJ; Zhang YJ; Xu J; Zheng L
    J Immunother Cancer; 2019 Nov; 7(1):300. PubMed ID: 31727135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of PRC2-associated factors in stem cells and disease.
    Vizán P; Beringer M; Ballaré C; Di Croce L
    FEBS J; 2015 May; 282(9):1723-35. PubMed ID: 25271128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.